← Eichor
Condition: Locally Advanced Or Metastatic Solid Tumors Harboring A Ros1 Synced from ClinicalTrials.gov · July 30, 2026

Recruiting studies: Locally Advanced Or Metastatic Solid Tumors Harboring A Ros1

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Phase 1/Phase 2 · 68 location(s) · Turning Point Therapeutics, Inc. · NCT04094610A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangement
Phase 1/Phase 2 · 165 location(s) · Turning Point Therapeutics, Inc. · NCT03093116A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 · 5 location(s) · Avistone Biotechnology Co., Ltd. · NCT06716138
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.